Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $309.2 million.

  • Krystal Biotech's Non-Current Assets fell 146.63% to $309.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 1491.47%. This contributed to the annual value of $309.2 million for FY2025, which is 146.63% down from last year.
  • Latest data reveals that Krystal Biotech reported Non-Current Assets of $309.2 million as of Q4 2025, which was down 146.63% from $314.4 million recorded in Q3 2025.
  • Krystal Biotech's Non-Current Assets' 5-year high stood at $314.4 million during Q3 2025, with a 5-year trough of $37.2 million in Q1 2021.
  • Its 5-year average for Non-Current Assets is $210.9 million, with a median of $204.1 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Krystal Biotech's Non-Current Assets was 38095.29% (2022), while the steepest drop was 508.46% (2022).
  • Over the past 5 years, Krystal Biotech's Non-Current Assets (Quarter) stood at $184.0 million in 2021, then decreased by 5.08% to $174.7 million in 2022, then soared by 31.93% to $230.4 million in 2023, then soared by 36.17% to $313.8 million in 2024, then fell by 1.47% to $309.2 million in 2025.
  • Its Non-Current Assets was $309.2 million in Q4 2025, compared to $314.4 million in Q3 2025 and $297.0 million in Q2 2025.